Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
GST-HG171 Tablets
DRUG
2 trials
Sponsors
Fujian Akeylink Biotechnology Co., Ltd.
Conditions
COVID-19 Pneumonia
Phase 1
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver Function
Completed
NCT06106113
Fujian Akeylink Biotechnology Co., Ltd.
COVID-19 Pneumonia
Start: 2022-12-15
End: 2023-05-30
Updated: 2023-10-30
Unknown Phase
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function
NCT06106126
Fujian Akeylink Biotechnology Co., Ltd.
COVID-19 Pneumonia
Start: 2023-02-10
End: 2024-03-01
Target: 32
Updated: 2023-10-30
Related Papers
Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling.
2026-07-15
Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function
Antimicrobial Agents and Chemotherapy
2024-07-11
4 citations